Finding sentinel and targeted lymph nodes with Magtrace and Magseed placed before chemotherapy
Official title: Axillary Lymph Node Identification Before Neoadjuvant Chemotherapy Using Magtrace, (Superparamagnetic Iron Oxide Nanoparticles, SPIO) and Magseed, in Clinically Node Negative and Node Positive Patients. SentiNeo 2.0
Run by Vastra Gotaland Region · NCT06104371 · Data updated 2026-11-12
This will test whether injecting a magnetic tracer (Magtrace) and placing a magnetic clip (Magseed) before neoadjuvant chemotherapy lets surgeons find the sentinel and targeted lymph nodes at surgery in people with breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 459 (estimated) |
| Sponsor | Vastra Gotaland Region Government |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Gothenburg) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | February 23, 2026 |
| Trial ID | NCT06104371 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with breast cancer scheduled for neoadjuvant chemotherapy who are planned for sentinel lymph node dissection or targeted axillary dissection are ideal candidates.
✕Probably not a fit
Patients who are pregnant or breastfeeding, have iron/dextran hypersensitivity or iron overload, require MRI for tumor response assessment, or cannot give informed consent are unlikely to be eligible or to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants receive a magnetic tracer injection before starting neoadjuvant chemotherapy, and surgeons attempt to detect those marked sentinel lymph nodes at surgery three to six months later. The team will also compare detection of nodes marked before chemotherapy with tracer injections given after chemotherapy to see if the same nodes are found. In patients who had proven lymph node metastasis before chemotherapy, one metastatic node is marked with a magnetic clip (Magseed) before treatment to allow targeted removal. The magnetic techniques are used alongside routine radioactive tracers and all patients receive standard-of-care treatment per national guidelines.
Why it matters
Potential benefit: If successful, this approach could improve accuracy of sentinel and targeted node identification after neoadjuvant chemotherapy and simplify axillary surgery planning.
How similar studies have gone: Magnetic tracers and magnetic clip marking have each been used successfully for node localization, but combining Magtrace injected before chemotherapy with Magseed-marked index nodes in this setting is relatively novel with limited direct data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Patients 18 years of age or older. * Patients with breast cancer planned to undergo NACT with * planned sentinel lymph node dissection (SLND), or * targeted axillary lymph node dissection (TAD), in conjunction with the * breast surgery after NACT. Exclusion Criteria: * Intolerance / hypersensitivity to iron or dextran compounds or SPIO. * Patients who are required to undergo MRI to evaluate tumour response. * Pregnancy or breast feedin.g * Patients with an iron overload disease. * Patient deprived of liberty or under guardianship. * Inability to understand given information and give informed consent or undergo study procedure
Where it's running
-
Sahlgrenska University Hospital
Gothenburg, Sweden Recruiting
Study contacts
- Study coordinator: Fredrik AM Warnberg, prof
- Email: fredrik.warnberg@vgregion.se
- Phone: +46706146251
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.